Dr Mark Litzow talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the novel indications for the use of an allogeneic haematopoietic stem cell transplantation (HSCT) for the treatment of acute lymphoblastic leukaemia (ALL).
He states that the use of a paediatric, intensive chemotherapy regimen is associated with better outcomes in young adults.
Dr Litzow also mentions the observation that patients with a negative MRD experienced better remission along with a more favourable outcome.
With these indications, along with additional genetic markers, he describes that a transplant may not be required for these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.